Glaukos Announces Participation in Upcoming Investor Conferences
11/19/2021 - 07:00 AM
SAN CLEMENTE, Calif. --(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:
Piper Sandler Annual Healthcare Conference (a pre-recorded fireside chat presentation will be available for viewing beginning on Monday, November 22, 2021 , at 10:00 a.m. EST ; management will participate in one-on-one and group meetings on Wednesday, December 1, 2021 )
Stephens Annual Investment Conference on Monday, November 29, 2021 , at 3:00 p.m. EST
A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com .
About Glaukos
Glaukos (www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent ® , its first MIGS device, in the United States in 2012, its next-generation iStent inject ® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
View source version on businesswire.com : https://www.businesswire.com/news/home/20211119005263/en/
Chris Lewis
clewis@glaukos.com
Source: Glaukos Corporation
GKOS Rankings
#908 Ranked by Stock Gains
GKOS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
San Clemente
About GKOS
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
